JCR
AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma
AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines
Actionable Insights Powered by AI
AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines